Mersana Therapeutics, Inc.
NASDAQ:MRSN
Overview | Financials
Company Name | Mersana Therapeutics, Inc. |
Symbol | MRSN |
Currency | USD |
Price | 1.84 |
Market Cap | 225,722,000 |
Dividend Yield | 0% |
52-week-range | 1.15 - 6.28 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Martin H. Huber Jr., M.D. |
Website | https://www.mersana.com |
An error occurred while fetching data.
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD